Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis

No abstract is available for this paper.

• Publication year

  2019

• Venue

  American Journal of Clinical Dermatology

• Publication date

  2019-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40257-019-00436-8PMID 30919315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab

  2018cited by this paper
• Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis

  2018cited by this paper
• Intramuscular Steroids in the Treatment of Dermatologic Disease: A Systematic Review.

  2018cited by this paper
• New and emerging targeted systemic therapies: a new era for atopic dermatitis

  2018cited by this paper
• A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis

  2017cited by this paper
• An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

  2016cited by this paper
• Weekend Ciclosporin Maintenance Therapy for Moderate Psoriasis

  2015cited by this paper
• Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis.

  2015cited by this paper
• FR-Terapia de mantenimiento con ciclosporina en pauta de fin de semana para psoriasis moderada

  2015cited by this paper
• Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications

  2015cited by this paper
• Weekend Ciclosporin Maintenance Therapy for Moderate Psoriasis.

  2015cited by this paper
• Oral Cyclosporine Weekend Therapy: A New Maintenance Therapeutic Option in Patients with Severe Atopic Dermatitis

  2015cited by this paper
• Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.

  2014cited by this paper
• Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

  2014cited by this paper
• “Eczema Coxsackium” and Unusual Cutaneous Findings in an Enterovirus Outbreak

  2013cited by this paper
• Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy.

  2013cited by this paper
• The use of cyclosporine in dermatology.

  2012cited by this paper
• The steroid withdrawal syndrome: a review of the implications, etiology, and treatments.

  2007cited by this paper

• Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis

  2026cites this paper
• An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis

  2025cites this paper
• Effect of dupilumab for the therapy of atopic dermatitis and the effect on serum TARC, HBD2 and SEA-IgE levels and peripheral blood T helper cell subtypes

  2025cites this paper
• Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial.

  2025cites this paper
• Real-life management of atopic dermatitis patients with an inadequate response to on-label use of dupilumab

  2024cites this paper
• 715 - Ruxolitinib: what’s stopping us?

  2024cites this paper
• OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

  2024cites this paper
• Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.

  2023cites this paper
• Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study.

  2023cites this paper
• Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis

  2022cites this paper
• Phenotypic differences of atopic dermatitis stratified by age

  2022cites this paper
• Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

  2021cites this paper
• Model-based meta-analysis to optimise S. aureus-targeted therapies for atopic dermatitis

  2021cites this paper
• Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

  2021cites this paper
• Getting personal about skin: Realizing precision medicine in dermatology

  2021cites this paper
• Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 clinical trial

  2021cites this paper
• Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

  2021cites this paper
• A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis

  2021cites this paper
• Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy

  2021cites this paper
• Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events

  2021cites this paper
• Severe Adult Atopic Dermatitis: Clinical Challenges

  2020cites this paper
• Patch Testing: Analysis of Internet-based Education Material

  2020cites this paper
• Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis.

  2020cites this paper
• Dupilumab use in atopic dermatitis and beyond in skin diseases.

  2020cites this paper
• Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

  2020cites this paper
• Patch Testing Interrupted: Virtual Patch Test Readings during the COVID-19 Pandemic

  2020cites this paper
• Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

  2020cites this paper
• Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable

  2020cites this paper
• Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable

  2020influential citation
• A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis

  2019cites this paper